ReShape Lifesciences Inc. (NASDAQ: RSLS)

Introduction

ReShape Lifesciences Inc. is a physician-led company focused on weight-loss and metabolic health solutions, providing an integrated portfolio of medical devices and services to manage obesity and metabolic disease. Key offerings include the FDA-approved Lap-Band® System for minimally invasive long-term weight loss and investigational technologies such as the ReShape Vest™ System and the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) platform. The company also delivers reshapecare® virtual health coaching to support lifestyle changes.

Corporate Structure

• Founded: 2002
• Headquarters: Eden Prairie, Minnesota
• Company Size: 11–50 employees
• Industry: Health, Wellness & Fitness; Medical Devices
• Specialties:
  • Obesity treatment
  • Metabolic disease management
  • Minimally invasive surgical devices
  • Virtual weight-management programs
• Notable Personnel:
  • Dr. Dov Gal, DVM, MBA – VP, Regulatory, Quality & Clinical
  • Charles Huang – VP, Sales & Marketing
  • Katie Reiter – Sales Operations Analyst

Developments & News

• September 19, 2024: The Board of Directors approved a 1-for-58 reverse stock split, effective September 23, 2024.
• November 2024: Health Canada approved the Lap-Band® 2.0 FLEX; the company secured a supplementary grant from the National Institutes of Health (~$241,000) for the development of next-generation DBSN™ electrodes.
• February 2025:
  • Completed a $6.0 million public offering of 2,575,107 units at $2.33 per unit (one share and one warrant).
  • Entered a distribution agreement with Liaison Medical for the Lap-Band® 2.0 FLEX in Canada.
• March 2025: Received a U.S. Notice of Allowance for patent application 17/046,677 covering multi-site vagus nerve modulation for glycemic control (patent protection until April 2039).
• April 7, 2025: Reported 2024 financial results—revenue of $8.0 million (−7.7% compared to 2023), gross profit of $5.1 million, operating expenses reduced by 41.9% (excluding M&A costs), and progress made on the merger agreement with Vyome Therapeutics as well as an asset purchase agreement with BioRad Medisys.
• May 30, 2025: Filed a prospectus (Form 424B5) for an “at-the-market” equity distribution agreement to sell up to $9.7 million of common stock through Maxim Group LLC.

Financial & Strategic Analysis

Metric	Value
Share Price (2025-06-03)	$5.9494 (+38.04%)
Volume (2025-06-03)	9,737,432 shares
52-Week Range	$4.03 – $414.70
Market Cap (intraday)	$4.39 million¹
Trailing P/E (TTM)	0.02
EPS (TTM)	264.12
Profit Margin (TTM)	−48.26%
Revenue (TTM)	$7.17 million
Net Income (TTM)	−$3.46 million
Total Cash (MRQ)	$2.52 million
Total Debt/Equity (MRQ)	10.57%
Equity Distribution Agreement	Up to $9.7 million

¹Source: Yahoo Finance as of 2025-05-30.

• Capital Structure & Funding: The reverse stock split was implemented to enhance compliance with Nasdaq requirements. The company completed a $6.0 million equity raise in February and has an additional at-the-market offering of up to $9.7 million to increase liquidity and support research and development as well as commercialization efforts.
• Profitability & Cash Management: Cost-reduction efforts resulted in a 41.9% decrease in operating expenses during 2024 (excluding M&A-related costs). The company continues to focus on cash management in light of net losses.
• Product Pipeline & Intellectual Property: The Notice of Allowance for the DBSN™ platform fortifies patent protection until 2039. An international patent was also granted by Israel for the vagus nerve modulation technology.

Market Position & Industry Context

• Core Market: The company operates in the obesity and metabolic disease treatment sector, offering minimally invasive devices as alternatives to traditional bariatric surgery and emerging pharmaceutical solutions (e.g., GLP-1 receptor agonists).
• Competitive Landscape:
  • Device-based competitors include intragastric balloons (Obalon®) and gastric bands (Lap-Band®); stomach-wrapping systems like the ReShape Vest™ are also included in the mix.
  • Pharmaceutical competition is primarily from GLP-1 receptor agonists which have an impact on accessory sales.
  • The growth of digital health offerings is supported through virtual coaching via reshapecare®.
• Strategic Partnerships: The distribution agreement in Canada with Liaison Medical, the pending merger with Vyome Therapeutics, and the asset sale to BioRad Medisys are initiatives aimed at focusing the company on novel immuno-inflammatory assets and enhancing its presence in the U.S.-India market.

tl;dr

• On June 3, 2025, RSLS shares closed at $5.9494 (+38.04%) on Nasdaq.
• On May 30, 2025, the company filed Form 424B5 to raise up to $9.7 million through an at-the-market equity agreement with Maxim Group LLC.
• A merger with Vyome Therapeutics and asset purchase by BioRad Medisys are both progressing; a shareholder vote is forthcoming.
• The company received a patent allowance in March 2025 for vagus nerve modulation technology related to diabetes, with an international patent in Israel extending protection to December 2039.
• In February 2025, ReShape raised $6.0 million and secured a Canadian distribution agreement for the Lap-Band® 2.0 FLEX.